Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation

Green S A; Malice M-P; Tanaka W; Tozzi C A; Reiss T F
February 2004
Thorax;Feb2004, Vol. 59 Issue 2, p100
Academic Journal
BACKGROUND: Leukotrienes play a key role in the pathophysiology of chronic asthma. Activation of leukotriene pathways is accompanied by rises in detectable urinary levels of leukotriene E4 (LTE4). The relationship between urinary LTE4 levels and factors associated with acute asthma has not been determined. METHODS: Adults aged 15-54 years presenting with moderate to severe acute asthma were evaluated at emergency departments in 16 US sites. Forced expiratory volume in 1 second (FEV1) was measured during the first 60 minutes after arrival and at specified times until discharge or admission. Urine samples for measurement of LTE4 levels were obtained either on arrival at the study site and/or before discharge. Patients were seen 2 weeks later for follow up, at which time repeat FEV1 measurements and urine samples for LTE4 were obtained. RESULTS: One hundred and eighty four patients were evaluated; LTE4 results from both the acute and follow up periods were available for analysis in 146. Urinary LTE4 levels were increased during asthma exacerbations compared with levels obtained 2 weeks later (geometric means 111.7 and 75.6 pg/mg creatinine, respectively, mean percentage change -32.3; 95% confidence interval (CI) for the mean percentage change -39.6 to -24.3, p<0.001). The correlation between improvement in FEV1 and decline in LTE4 over the 2 week interval was significant (p<0.001, r=0.43). CONCLUSIONS: Activation of leukotriene pathways in acute asthma is correlated with the degree of airflow obstruction, and resolution of the asthma exacerbation is associated with a reduction in leukotriene levels.


Related Articles

  • Zafirlukast: An Update of its Pharmacology and Therapeutic Efficacy in Asthma. Dunn, C.J.; Goa, K.L. // Drugs;Jan2001, Vol. 61 Issue 2, p285 

    Zafirlukast is a selective and competitive orally administered inhibitor of the cysteinyl leukotrienes LTC, LTD and LTE. The drug is indicated for the prophylaxis and treatment of chronic asthma, and has been developed in response to mounting evidence indicating the importance of the cysteinyl...

  • A local perspective to asthma management in the accident and emergency department in Malta. Gouder, Caroline; Micallef, Josef; Asciak, Rachelle; Preca, Justine Farrugia; Pullicino, Richard; Montefort, Stephen // Lung India; 

    Aim: This study was performed to assess the management of adult patients presenting to the Mater Dei Hospital Accident and Emergency (A&E) department with acute asthma. Subjects and Methods: Asthmatic patients age 14 or older who presented to A&E department between January and October 2010 with...

  • Third of cancers in over-70s found on attendance at A&E. Berry, Lisa // Cancer Nursing Practice;Oct2012, Vol. 11 Issue 8, p4 

    The article reports that according to the National Cancer Intelligence Network (NCIN) almost one third of cancers in people aged over 70 years are diagnosed each year when they visit the emergency department.

  • Medical Therapy for Asthma: Updates from the NAEPP Guidelines. ELWARD, KURTIS S.; POLLART, SUSAN M. // American Family Physician;11/15/2010, Vol. 82 Issue 10, p1242 

    Proper care of patients with asthma involves the triad of systematic chronic care plans, self-management support, and appropriate medical therapy. Controller medications (inhaled corticosteroids, long-acting beta2 agonists, and leukotriene receptor antagonists) are the foundation of care for...

  • Pharmacogenetics of Asthma Therapy. Qing Ling Duan; Tantisira, Kelan G. // Current Pharmaceutical Design;11/11/2009, Vol. 15 Issue 32, p3742 

    Asthma is a chronic disorder causing inflammation and reversible airway obstruction that affects approximately 300 million individuals worldwide. The incidence of asthma has nearly doubled in the past three decades resulting in higher rates of morbidity, mortality and health care costs. Despite...

  • Blocking leukotrienes optimize asthma control: The BLOC survey. Idrees, Majdy M.; Al Moamary, Mohamed S. // Annals of Thoracic Medicine;Jul-Sep2007, Vol. 2 Issue 3, p99 

    Objective: The aim of this study was to evaluate asthma control after the introduction of a leukotriene modifier (Montelukast), in addition to the current controller asthma therapies, in patients with inadequately controlled mild-to-moderate persistent asthma. Asthma control and patient...

  • New drug hope for child asthma.  // Pulse;6/8/2006, Vol. 66 Issue 23, p2 

    The article talks about leukotriene receptor antagonist as a means of controlling symptoms in children with mild asthma. According to a study of general practice in Great Britain, it is substantially better to use a leukotriene receptor antagonist than inhaled steroids in controlling the...

  • Singulair.  // Royal Society of Medicine: Medicines;2002, p496 

    The article presents information on the Singulair drug which is a proprietary, prescription-only preparation of the anti-allergic and anti-asthmatic drug montelukast, a leukotriene-receptor antagonist. This drug is used for the prevention of asthma symptoms. It is available as chewable tablets...

  • Once-daily oral leukotriene blocker is cleared for the treatment of asthma.  // Modern Medicine;Apr98, Vol. 66 Issue 4, p58 

    Introduces Montelukast sodium, an oral leukotriene blocker for the treatment of asthma in patients aged six years and older. Mechanism of action of the drug; Side effects.


Read the Article


Sign out of this library

Other Topics